{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-054486","form_type":"8-K","ticker":null,"cik":"0001808158","company_name":"Repare Therapeutics Inc.","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.234902+00:00","generated_at":"2026-06-02T19:40:24.461472+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Repare Therapeutics reports Q1 net income $13.2M; FDA agrees on RP2D for lunresertib+camonsertib combination","bullets":["Net income of $13.2M ($0.30 diluted) vs loss of $34.9M a year ago; revenue $52.4M primarily from $40M Roche milestone.","Cash, equivalents and marketables $237M, sufficient to fund operations at least into mid-2026.","FDA agreed to RP2D for lunresertib 80mg BID + camonsertib 80mg QD; Grade 3 anemia reduced to 25% from 45%.","Regained global rights to camonsertib from Roche; cumulative $182.6M received from Roche under collaboration.","First patient dosed in Phase 1 LIONS trial of PLK4 inhibitor RP-1664; expecting pivotal trial start for lunresertib combo in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-054486","json":"https://secwatch.observer/filing/0000950170-24-054486.json","markdown":"https://secwatch.observer/filing/0000950170-24-054486.md","text":"https://secwatch.observer/filing/0000950170-24-054486.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1808158/000095017024054486/0000950170-24-054486-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1808158/000095017024054486/rptx-20240507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T19:40:24.461472+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bd3cabc30ade8488f39bcf18e82df398534b067f","claim":"Repare Therapeutics Inc. reported financial results for first quarter ended March 31, 2024.","evidence_excerpt":"On May 7, 2024, Repare Therapeutics Inc. (the \"Company\") issued a press release announcing its recent business highlights and financial results for the three months ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1808158/000095017024054486/0000950170-24-054486-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}